204 related articles for article (PubMed ID: 24905655)
1. Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions.
Mullins JK; Carter HB
BJU Int; 2014 Jun; 113(6):844-5. PubMed ID: 24905655
[No Abstract] [Full Text] [Related]
2. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance.
Park BH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
BJU Int; 2014 Jun; 113(6):864-70. PubMed ID: 24053308
[TBL] [Abstract][Full Text] [Related]
3. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
[TBL] [Abstract][Full Text] [Related]
4. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.
Felker ER; Wu J; Natarajan S; Margolis DJ; Raman SS; Huang J; Dorey F; Marks LS
J Urol; 2016 May; 195(5):1421-1427. PubMed ID: 26674305
[TBL] [Abstract][Full Text] [Related]
5. Imaging Characteristics of Prostate Cancer Patients Who Discontinued Active Surveillance on 3-T Multiparametric Prostate MRI.
Habibian DJ; Liu CC; Dao A; Kosinski KE; Katz AE
AJR Am J Roentgenol; 2017 Mar; 208(3):564-569. PubMed ID: 28075651
[TBL] [Abstract][Full Text] [Related]
6. [Magnetic resonance imaging facilitate appropriate treatment selection of prostate cancer patients].
Boesen L; Thomsen HS
Ugeskr Laeger; 2013 Jun; 175(23):1634-7. PubMed ID: 23731990
[TBL] [Abstract][Full Text] [Related]
7. The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.
Schulman AA; Sze C; Tsivian E; Gupta RT; Moul JW; Polascik TJ
Curr Urol Rep; 2017 Jul; 18(7):52. PubMed ID: 28589398
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.
Yoo S; Kim JK; Jeong IG
Korean J Urol; 2015 Jul; 56(7):487-97. PubMed ID: 26175867
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric magnetic resonance imaging in the detection of prostate cancer.
Durmus T; Baur A; Hamm B
Aktuelle Urol; 2014 Mar; 45(2):119-26. PubMed ID: 24700068
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
[TBL] [Abstract][Full Text] [Related]
11. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
12. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
[TBL] [Abstract][Full Text] [Related]
13. Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer.
Goldberg H; Klaassen Z; Chandrasekar T; Fleshner N
Curr Opin Urol; 2018 Jan; 28(1):46-54. PubMed ID: 29028765
[TBL] [Abstract][Full Text] [Related]
14. Current concepts in multiparametric magnetic resonance imaging for active surveillance of prostate cancer.
Cavalcante A; Viana PCC; Guglielmetti GB; Pontes Junior J; Nonemacher H; Cordeiro MD; Bezerra ROF; Coelho RF; Nahas WC
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e464s. PubMed ID: 30540118
[No Abstract] [Full Text] [Related]
15. The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
Ma TM; Tosoian JJ; Schaeffer EM; Landis P; Wolf S; Macura KJ; Epstein JI; Mamawala M; Carter HB
Eur Urol; 2017 Feb; 71(2):174-180. PubMed ID: 27236496
[TBL] [Abstract][Full Text] [Related]
16. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
17. Active Surveillance for Prostate Cancer and Small Renal Masses: New Evidences and Criticisms.
Prudhomme M
Anticancer Agents Med Chem; 2018; 18(7):924. PubMed ID: 30608035
[No Abstract] [Full Text] [Related]
18. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
Park JJ; Park BK
J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy.
Vasarainen H; Lahdensuo K; Savolainen R; Ruutu M; Taari K; Rannikko A
Scand J Urol; 2013 Dec; 47(6):456-61. PubMed ID: 23327661
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes.
Dianat SS; Carter HB; Pienta KJ; Schaeffer EM; Landis PK; Epstein JI; Trock BJ; Macura KJ
Urology; 2015 Jan; 85(1):147-53. PubMed ID: 25440986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
